Genocea Biosciences Stock Cash And Equivalents
| GNCADelisted Stock | USD 0.0002 0.0001 100.00% |
Genocea Biosciences fundamentals help investors to digest information that contributes to Genocea Biosciences' financial success or failures. It also enables traders to predict the movement of Genocea Stock. The fundamental analysis module provides a way to measure Genocea Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genocea Biosciences stock.
Genocea |
Genocea Biosciences Company Cash And Equivalents Analysis
Genocea Biosciences' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Genocea Biosciences Cash And Equivalents | 20.14 M |
Most of Genocea Biosciences' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genocea Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Genocea Biosciences has 20.14 M in Cash And Equivalents. This is 97.55% lower than that of the Biotechnology sector and 95.5% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.25% higher than that of the company.
Genocea Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genocea Biosciences' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genocea Biosciences could also be used in its relative valuation, which is a method of valuing Genocea Biosciences by comparing valuation metrics of similar companies.Genocea Biosciences is currently under evaluation in cash and equivalents category among its peers.
Genocea Fundamentals
| Return On Equity | -5.26 | |||
| Return On Asset | -0.58 | |||
| Operating Margin | (29.59) % | |||
| Current Valuation | (4.53 M) | |||
| Shares Outstanding | 58.78 M | |||
| Shares Owned By Insiders | 6.22 % | |||
| Shares Owned By Institutions | 1.25 % | |||
| Number Of Shares Shorted | 1.64 M | |||
| Price To Earning | (0.59) X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.12 X | |||
| Revenue | 1.64 M | |||
| Gross Profit | 1.64 M | |||
| EBITDA | (34.32 M) | |||
| Net Income | (33.2 M) | |||
| Cash And Equivalents | 20.14 M | |||
| Cash Per Share | 0.34 X | |||
| Total Debt | 8.79 M | |||
| Debt To Equity | 1.25 % | |||
| Current Ratio | 1.35 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (45.37 M) | |||
| Short Ratio | 0.74 X | |||
| Earnings Per Share | (0.53) X | |||
| Target Price | 3.08 | |||
| Number Of Employees | 74 | |||
| Beta | 1.6 | |||
| Market Capitalization | 5.88 K | |||
| Total Asset | 55.97 M | |||
| Retained Earnings | (339.66 M) | |||
| Working Capital | 69.32 M | |||
| Current Asset | 76.41 M | |||
| Current Liabilities | 7.09 M | |||
| Z Score | -7.2 | |||
| Net Asset | 55.97 M |
About Genocea Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genocea Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genocea Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genocea Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Genocea Stock
If you are still planning to invest in Genocea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genocea Biosciences' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |